Physician profile
Jack Thomas Mcafee
NPI 1659477032
$7,682.94
in general payments reported to CMS, 2019-2025
49 companies · $2,683 in 2025
The $2,683 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,369 · 2024: $2,631 · 2025: $2,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,615 · Education: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,615.09 |
| Education | $1,067.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $837.75 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $530.17 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $501.87 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $500.35 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $397.29 | 2023-2025 | Enhertu, Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $358.81 | 2024-2025 | |
| Janssen Biotech, INC. | $353.67 | 2023-2025 | Erleada, Rybrevant, Carvykti |
| Regeneron Healthcare Solutions, INC. | $321.02 | 2023-2025 | Libtayo |
| Gilead Sciences, INC. | $295.58 | 2023-2025 | Trodelvy |
| Pfizer INC. | $273.95 | 2024-2025 | |
| Celgene Corporation | $269.19 | 2023-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $247.95 | 2023-2025 | Tecentriq, Phesgo, Itovebi |
| Mirati Therapeutics, INC. | $226.52 | 2023-2024 | Krazati |
| Daiichi Sankyo INC. | $208.66 | 2023-2024 | Enhertu, Injectafer |
| Seagen INC. | $177.11 | 2023 | Tukysa, Adcetris |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $168.65 | 2023-2025 | Ninlaro, Fruzaqla, Vpriv |
| Exelixis INC. | $167.00 | 2023-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $164.37 | 2023-2025 | |
| Genzyme Corporation | $149.27 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $117.42 | 2023-2025 | Fotivda |
| Eisai INC. | $105.03 | 2023-2025 | |
| Array Biopharma INC | $99.19 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Abbvie INC. | $94.91 | 2024 | |
| Jazz Pharmaceuticals INC. | $90.06 | 2023-2025 | |
| Emd Serono, INC. | $82.90 | 2023-2024 | Bavencio, Tepmetko |
| Beigene USA, INC. | $81.11 | 2024-2025 | Brukinsa, Tevimbra |
| Taiho Oncology, INC. | $68.47 | 2024-2025 | |
| Beone Medicines USA, INC. | $66.77 | 2025 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $57.29 | 2023-2025 | Besremi |
| Myriad Genetic Laboratories, INC. | $55.52 | 2023-2025 | Myrisk, Precisetumor |
| Astellas Pharma US INC | $54.78 | 2023-2024 | Xtandi |
| Glaxosmithkline, LLC. | $50.46 | 2025 | Ojjaara, Jemperli, Zejula |
| Deciphera Pharmaceuticals INC. | $50.09 | 2023-2025 | Qinlock, Romvimza |
| Agios Pharmaceuticals, INC. | $49.10 | 2023 | Pyrukynd |
| Morphosys, US INC. | $48.02 | 2023 | Monjuvi |
| Novocure INC. | $46.78 | 2025 | Optune Lua (Novottf-200t) |
| Ucb, INC. | $45.21 | 2025 | Rystiggo |
| Tersera Therapeutics LLC | $35.08 | 2023-2024 | Xermelo, Zoladex |
| Ipsen Biopharmaceuticals, INC | $29.83 | 2025 | Onivyde |
| Sun Pharmaceutical Industries INC. | $29.18 | 2024 | |
| Springworks Therapeutics, INC. | $27.72 | 2025 | Ogsiveo |
| Recordati_rare_diseases_inc. | $23.26 | 2025 | Enjaymo |
| Foundation Medicine, INC. | $22.76 | 2023 | |
| Genmab U.S., INC. | $19.35 | 2023 | Epkinly |
| Alexion Pharmaceuticals, INC. | $18.71 | 2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $17.82 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Amgen INC. | $17.00 | 2023 | Nplate, Vectibix, Xgeva |
| Apellis Pharmaceuticals, INC. | $14.97 | 2023 | Empaveli |
| Kyowa Kirin, INC. | $14.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Mcafee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.